Minding The Gap: Pazdur Compares FDA, EMEA Approaches
ORLANDO, Fla. - "EMEA is not the FDA of Europe, and the FDA is not the EMEA of the United States." That's how Richard Pazdur - the head of FDA's Office of Oncology Drug Products - started off a panel on oncology regulatory initiatives at ASCO on May 30
You may also be interested in...
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
“The spin-off will establish two separate companies, a fully integrated, pure play, eye health company built on the iconic Bausch Health brand and a long history of innovation, and an international diversified pharmaceutical company with leading physicians in gastroenterology, dermatology, aesthetics, neurology and an international pharma business,” says CEO Joseph Papa.